Generated Summary
The document is the 2019 Antibiotic Resistance Threats Report by the CDC, which details the national death and infection estimates for 18 antimicrobial-resistant bacteria and fungi in the United States. This report builds on the 2013 report and underlines the ongoing threat of antimicrobial resistance (AR) in the U.S. It underscores the need to combat AR and highlights actions taken to combat this threat, as well as the gaps in progress. The report includes national death and infection estimates for 18 antimicrobial-resistant bacteria and fungi. The CDC lists germs in three categories: urgent, serious, and concerning, as well as a watch list. The 2019 report also emphasizes the progress made in combating AR. However, the 2022 special report highlights the impact of COVID-19 on antimicrobial resistance, which caused a loss of progress due to the pandemic. The document provides a reference for information on AR, provides the latest AR burden estimates for human health in the U.S., and highlights emerging areas of concern and additional action needed. The report also intends to serve as a reference for information on AR, provide the latest AR burden estimates for human health in the U.S., and highlight emerging areas of concern and additional action needed.
Key Findings & Statistics
- More than 2.8 million antimicrobial-resistant infections occur in the U.S. each year.
- More than 35,000 people die as a result.
- When C. diff is added to these, the U.S. toll of all the threats in the report exceeds 3 million infections and 48,000 deaths.
- In July 2024, CDC published Antimicrobial Resistance Threats in the United States, 2021-2022.
- These new data show that six bacterial antimicrobial-resistant hospital-onset infections increased by a combined 20% during the COVID-19 pandemic compared to the pre-pandemic period, peaking in 2021, and remaining above pre-pandemic levels in 2022.
- The number of reported clinical cases of Candida auris (C. auris) – a type of yeast that can spread in healthcare facilities, is often resistant to antifungal medications, and can cause severe illness-increased nearly five-fold from 2019 to 2022.
- Carbapenem-resistant Acinetobacter: 8,500 estimated cases in hospitalized patients in 2017, 700 estimated deaths in 2017, and $281M estimated attributable healthcare costs in 2017.
- Drug-resistant Candida Auris: 323 clinical cases in 2018.
- Clostridioides difficile: 223,900 estimated cases in hospitalized patients in 2017, 12,800 estimated deaths in 2017, and $1B estimated attributable healthcare costs in 2017.
- Carbapenem-resistant Enterobacteriaceae: 13,100 estimated cases in hospitalized patients in 2017, 1,100 estimated deaths in 2017, and $130M estimated attributable healthcare costs in 2017.
- Drug-resistant Neisseria gonorrhoeae: 550,000 estimated drug-resistant infections each year, and 1.14M total new infections each year, with annual discounted lifetime direct medical costs of $133.4M.
- Drug-resistant Campylobacter: 448,400 estimated infections each year, and 70 estimated deaths each year.
- Drug-resistant Candida species: 34,800 estimated cases in hospitalized patients in 2017, and 1,700 estimated deaths in 2017.
- Extended-spectrum beta-lactamase (ESBL) producing enterobacteriaceae: 197,400 estimated cases in hospitalized patients in 2017, 9,100 estimated deaths in 2017, and $1.2B estimated attributable healthcare costs in 2017.
- Vancomycin-resistant enterococci (VRE): 54,500 estimated cases in hospitalized patients in 2017, 5,400 estimated deaths in 2017, and $539M estimated attributable healthcare costs in 2017.
- Multidrug-resistant Pseudomonas aeruginosa: 32,600 estimated cases in hospitalized patients in 2017, 2,700 estimated deaths in 2017, and $767M estimated attributable healthcare costs in 2017.
- Drug-resistant nontyphoidal Salmonella: 212,500 estimated infections each year, and 70 estimated deaths each year.
- Drug-resistant Salmonella serotype Typhi: 4,100 estimated infections each year, and less than 5 estimated deaths each year.
- Drug-resistant Shigella: 77,000 estimated infections each year, and less than 5 estimated deaths each year.
- Methicillin-resistant Staphylococcus aureus (MRSA): 323,700 estimated cases in hospitalized patients in 2017, 10,600 estimated deaths in 2017, and $1.7B estimated attributable healthcare costs in 2017.
- Drug-resistant Streptococcus pneumoniae: 900,000 estimated infections in 2014, and 3,600 estimated deaths in 2014.
- Drug-resistant Tuberculosis (TB): 847 cases in 2017, and 62 deaths in 2017.
- Erythromycin-resistant group A Streptococcus: 5,400 estimated infections in 2017, and 450 estimated deaths in 2017.
- Clindamycin-resistant group B Streptococcus: 13,000 estimated infections in 2016, and 720 estimated deaths in 2016.
Other Important Findings
- The 2019 AR Threats Report is intended to serve as a reference for information on AR, provide the latest AR burden estimates for human health in the U.S., and highlight emerging areas of concern and additional action needed.
- The germs are listed in three categories—urgent, serious, and concerning—based on level of concern to human health. The report also includes a Watch List with three threats that have not spread widely in the U.S. but could become common without continued aggressive action.
- Starting in 2025, CDC will release estimates for at least 19 antimicrobial resistance threats and an update on the U.S. burden of antimicrobial resistance, by pathogen, in a new electronic format.
- CDC is committed to providing the high-quality data required to steer this important work.
- The 2013 AR Threats Report helped inform the first National Action Plan for Combating Antibiotic- Resistant Bacteria.
Limitations Noted in the Document
- The 2013 and 2019 reports do not include viruses (e.g., HIV, influenza) or parasites.
Conclusion
The CDC’s 2019 Antibiotic Resistance Threats Report underscores the continued threat of antimicrobial resistance in the U.S., highlighting national death and infection estimates for various antimicrobial-resistant bacteria and fungi. The report categorizes these threats into urgent, serious, and concerning, as well as a watch list, emphasizing the need for continued efforts to combat AR. While the report acknowledges progress in combating AR, it also highlights the setbacks caused by the COVID-19 pandemic, which disrupted healthcare systems and slowed advancements. The report provides a reference for AR information, burden estimates, and emerging areas of concern. It aims to guide U.S. policy and investments in combating antimicrobial resistance. The data is critical to guide efforts to combat antimicrobial resistance, and the CDC is committed to providing the high-quality data required to steer this important work. The findings underscore the urgency of the situation, with millions of infections and tens of thousands of deaths attributed to AR annually. The rise in infections, particularly during the COVID-19 pandemic, highlights the need for additional action to slow the spread and impact of antimicrobial resistance. This document is a call to action for the public, healthcare providers, and policymakers to take steps to combat antimicrobial resistance and protect public health. The work requires heightened vigilance and public health engagement to contain resistance threats wherever and whenever they emerge. Swift public health action is fundamental to save lives.